Venatorx Pharma has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of antimicrobial ...

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs) that will now launch later this year, but turned down a rival product ...

In January 2025, Wockhardt announced that ZAYNICH demonstrated unprecedented efficacy in a global, pivotal Phase III study ...

Wockhardt files for European marketing approval of WCK 5222, a novel antibiotic targeting multi-drug resistant infections.

The EMA is the regulatory authority responsible for the scientific evaluation, of new medicines across the 27 European Union (EU) Member States and three European Economic Area (EEA) countriesIceland, ...

The European Medicines Agency (EMA) has informed Wockhardt that WCK 5222 (combination of Zidebactam 1g + Cefepime 2g) is eligible for Accelerated Assessment, following a pre-submission meeting with ...

Mumbai: Wockhardt has announced that it has been informed by the European Medicines Agency (EMA) that WCK 5222, a combination ...

In a major breakthrough for India's pharmaceuticals and public health, Wockhardt has developed a brand-new antibiotic named Zaynich, intended specifically to tackle a class of multi-drug resistant ...

Pune: An indigenously developed antibiotic has emerged as a "blessing" in the treatment of complicated urinary tract infections (UTIs) among Indian patients, said Dr V Balaji, professor of clinical ...

Wockhardt Limited announced today that its novel antibiotic Zaynich (Zidebactam/Cefepime, WCK 5222) achieved over 97 per cent clinical efficacy in treating serious infections caused by ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...